Patients with type 2 diabetes who received intravitreal anti-vascular endothelial growth factor (VEGF) injections for diabetic retinopathy were more likely to develop systemic adverse events (AEs) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback